
About Juvena Therapeutics
Juvena Therapeutics is a Healthcare company based in San Mateo (United States) founded in 2017 by Jeremy O'Connell and Hanadie Yousef. Protein-based therapies for sarcopenia and muscle regeneration are developed. Juvena Therapeutics has raised $75.81 million across 4 funding rounds from investors including HHS, Mubadala and Plum Alley Investments. Its chief executive, as recorded, is Hanadie Yousef. Juvena Therapeutics offers products and services including JUV-161 and Secreted Proteins Platform. Its focus areas include Life Sciences, Orthopedics, Drugs and Muscle Disorders. Its legal entity is Juvena Therapeutics Inc. Its competitors include Altimmune, Carmot and BioAge Labs; 3 of its 3 listed competitors have raised funding.
Company details
Juvena Therapeutics was founded in 2017 in San Mateo, United States, within the biotechnology sector. Protein-based therapeutics are developed by the company to promote tissue generation in the elderly, with a focus on sarcopenia and muscle regeneration. A discovery platform is utilized for screening restored muscle function, which can be extended to other tissue types. A protein cocktail has been created to enhance healing, regeneration, and appearance in aged muscle.
- Headquarters San Mateo, United States
- Founders Jeremy O'Connell, Hanadie Yousef
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website juvenatherapeutics.com
- Social LinkedIn
- Legal Name Juvena Therapeutics Inc.
- Total Equity Funding$75.81M (USD)
in 4 rounds
- Latest Funding Round$30.49M (USD), Series A
Jun 2025
- InvestorsHHS
& 13 more
Products & Services of Juvena Therapeutics
Juvena Therapeutics offers a comprehensive portfolio of products and services, including JUV-161 and Secreted Proteins Platform.
Biologic targeting Myotonic Dystrophy Type 1 for muscle degeneration repair
Tool for mapping and engineering proteins to treat metabolic diseases
Funding Insights of Juvena Therapeutics
Juvena Therapeutics has successfully raised a total of $75.81M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $30.49 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $75.81M
- Total Rounds 4
- Last Round Series A β $30.49M
- First Round $4.31M
(Feb 2018)
- Investors Count 14
All 4 funding rounds of Juvena Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | $30.49M | Series A | β | β | β |
| Nov 2022 | $41M | Series A | β | Mubadala, Horizons Ventures | |
| Sep 2021 | $254,262 | Grant | β | β | |
| Feb 2018 | $4.31M | Series A | β | β | β |
14 investors in total: 13 institutional and 1 angel.
Investors in Juvena Therapeutics
Juvena Therapeutics has secured backing from 14 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include HHS, Mubadala and Plum Alley Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Horizons Ventures is focused on investing in deep science and technology. | horizonsventures.com | Hong Kong, China | ||
Bison Ventures is focused on investing in frontier technology companies. | bison.vc | San Francisco, United States | ||
| mantarayventures.com | ||||
Venture capital firm focused on Web 3 | Seoul, South Korea | |||
Venture capital investing and portfolio management services for accredited investors. | av.vc | |||
Early-stage technology companies are funded by Transform VC. | transform.vc | San Francisco, United States | ||
Early-stage companies are invested in by BoxOne Ventures. | boxone.xyz | Montreal, Canada | ||
| intersectvc.com | ||||
Compound is recognized as a thesis-driven investment firm. | compound.vc | New York, United States | ||
Investments in technology startups are made by Felicis Ventures. | felicis.com | Menlo Park, United States |
Investor details for Juvena Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Juvena Therapeutics
39 people are tracked at Juvena Therapeutics (5 in leadership, 17 in board & advisors, 17 in team).
| Name | Role | Group |
|---|---|---|
Jeremy O'Connell | Co-Founder & CSO | Leadership |
Hanadie Yousef | Co-Founder & CEO | Leadership |
Fengling Liu | Director of Protein Science | Leadership |
Banmeet Anand | Senior Vice President Drug Development | Leadership |
Skanda Goudar | Sr. Director, Alliance Management And Program Management | Leadership |
Stephen Juelsgaard | Director | Board & advisors |
Patrick Zhang | Director | Board & advisors |
Irina Conboy | Scientific Advisor | Board & advisors |
Peter Jackson | Scientific Advisor | Board & advisors |
Joe Wu | Scientific Advisor | Board & advisors |
Nicholas E. Johnson | Advisor | Board & advisors |
Jeff Welch | Advisor | Board & advisors |
Ayman Alabdallah | Director | Board & advisors |
Lawrence Barclay | Director | Board & advisors |
Ben Hemani | Director | Board & advisors |
Ameet Mallik | Business Advisor | Board & advisors |
Matthew Fust | Business Advisor | Board & advisors |
Mark Leslie | Business Advisor | Board & advisors |
Mike Nohaile | Business Advisor | Board & advisors |
David Schaffer | Scientific Advisor | Board & advisors |
19 more people are available in the full profile.
Complete people profiles for Juvena Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Juvena Therapeutics
3 dated milestones of Juvena Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Juvena Therapeutics is founded.
- Funding First funding round of $4.3M.
- Funding Latest funding round, Series A, of $30.5M.
Competitors of Juvena Therapeutics
Juvena Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Altimmune, Carmot and BioAge Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. | |
| carmot.us | 2008 | Berkeley, United States | $385.52M | Disease-modifying therapies for metabolic diseases are developed. | ||
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. |
Detailed competitors of Juvena Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Juvena Therapeutics
The website of Juvena Therapeutics (juvenatherapeutics.com) receives about 3.4K visits a month.
- Monthly visits3.4K
▼ 22.7% vs previous month
Top companies in Orthopedics
3 companies that operate in the same segment as Juvena Therapeutics (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Juvena Therapeutics
Juvena Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Juvena Therapeutics is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Hanadie Yousef is the CEO of Juvena Therapeutics, as recorded in our data. They have also founded this company.
Juvena Therapeutics is a funded company, having raised a total of $75.81M across 4 funding rounds to date. The company's 1st funding round was a Series A of $4.31M, raised on Feb 2018.
Juvena Therapeutics was founded in 2017 in San Mateo, United States, within the biotechnology sector. Protein-based therapeutics are developed by the company to promote tissue generation in the elderly, with a focus on sarcopenia and muscle regeneration. A discovery platform is utilized for screening restored muscle function, which can be extended to other tissue types. A protein cocktail has been created to enhance healing, regeneration, and appearance in aged muscle.
Juvena Therapeutics's top competitors include BioAge Labs, Carmot and Altimmune.
Juvena Therapeutics offers JUV-161 and Secreted Proteins Platform.
Juvena Therapeutics has 14 investors. Key investors include HHS, Mubadala, Plum Alley Investments, Horizons Ventures, and Bison Ventures.
Juvena Therapeutics operates through Juvena Therapeutics Inc..